A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human phase I, multicenter, open label, sequential-cohort, dose escalation
study of ESG206. The purpose is to evaluate the clinical safety, tolerability, PK, and
preliminary efficacy and to establish the MTD, if any, and RP2D(s) of ESG206 in adult
subjects with B lymphoid malignancies.